Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

摘要: Background Peritoneal metastases in patients with high-grade adenocarcinoma have been typically associated a poor outcome. Recent literature has suggested that cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may improve survival. We examined this subset of an effort to better delineate those factors which contribute improved Methods A retrospective review was performed looking at who had undergone CRS/HIPEC. Patients were identified as histology on the basis pathology reports indicating their lesion high grade, moderately, or poorly differentiated and/or signet ring goblet cell carcinoid features. cancer index completeness (CC) used define disease burden. Survival analysis by method Kaplan-Meier log-rank test determine significance. Results Of 250 underwent CRS/HIPEC between 1999 2011, 36 (14%) having peritoneal from gastrointestinal primary. Actual overall survival time diagnosis 11.1% 5 years. Median 21.6 months. advantage conferred CC0/CC1 resection, score ≤20, appendiceal primary, moderately histopathology. Receipt neoadjuvant nodal status not significantly predictive particularly prognosis. Conclusion For historically prognosis, prolonged be achieved through CRS/HIPEC, optimally resection.